PR Newswire

TEL AVIV, Israel, Sept. 16, 2026 /PRNewswire/ — Lutris Pharma, a clinical stage biopharmaceutical company focused on improving the quality of life and drug adherence for patients treated with anti-cancer therapies by mitigating dermatological toxicities, today announced the presentation of updated results from its phase 2,